Compare IDEXX Laboratories, Inc. (IDXX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tripadvisor Inc Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B). The key difference: IDEXX Laboratories, Inc. is far larger — about 40× Tripadvisor Inc Common Stock's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 3,004,748). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| IDXX | TRIP | |
|---|---|---|
Market Cap | $40.43B | $1.01B |
Volume | 692,164 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $16.72 |
52-Week Low | $504.70 | $8.04 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | $41.32B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
TripAdvisor (TRIP) trades at $8.96, up 3.82% today but near 52-week lows, with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported Q2 2026 earnings of $0.35 per share, missing estimates, while revenue trends show modest growth from $1.5B in 2022 to $1.9B in 2025. Analyst consensus is mixed with 62.5% hold ratings and a $13.58 price target, representing 52% upside potential from current levels.
The investment case hinges on TripAdvisor's ability to stabilize its core business amid AI disruption in travel planning. While valuation appears reasonable with P/S of 0.57 and EV/EBITDA of 6.28, recent earnings misses and competitive pressures from AI platforms create significant headwinds. The stock offers substantial upside if management can execute on growth initiatives, but faces execution risk in a rapidly evolving travel technology landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
